



JOIN OUR LIVESTREAM

THE VALUE OF POINT-OF-CARE TESTING IN DIABETES AND COMORBIDITIES MANAGEMENT IN THE CONTEXT OF COVID-19

30 November at 15:30–17:00 CET
CPD | CME ACCREDITED



REGISTER HERE – IT'S FREE

Can't make it to the livestream? Don't worry.
Register anyway and you can watch it on demand.

BACKGROUND

Join our panel of experts from around the world for this compelling event presenting a view from the front line on the management of diabetes patients and comorbidities in the context of COVID-19.

With telehealth and remote treatment on the rise, a unique and international group of experts will analyse how rapid HbA1c and lipid point-of-care testing may benefit patients with diabetes in the COVID-19 healthcare landscape and beyond. We will also have a closer look at the accuracy of HbA1c point-of-care testing.

Screening and monitoring of diabetes and cardiovascular patients is even more critical these days. According to the World Health Organisation, individuals may be more susceptible to severe COVID-19 and death if they have a noncommunicable disease, such as diabetes, high blood pressure, cardiac disease, kidney disease, chronic lung disease, cerebrovascular disease or cancer.¹ Diabetes has not yet been shown to increase the likelihood of SARS-CoV-2 infection, but progression to severe illness is more likely in people with diabetes.² The frequency of diabetes among COVID-19 patients requiring hospitalisation or intensive care is two to three times higher than in the overall population, and mortality rates in those with diabetes are also higher.²⁻⁸

Point-of-care testing for HbA1c aids in achieving improved glycaemic control with just one office visit.⁹⁻¹²



Presentations will be held in English, but there will be subtitles available in German and French.

PRESENTATIONS



CHAIR
PROF. OLIVER SCHNELL
(Germany)

Welcome and Introductions



SPEAKER
PROF. BERND SCHULTES
(Switzerland)

Insights from a Swiss competence centre for diabetology




SPEAKER
DR. DEVAKI NAIR
(England)

COVID-19 and diabetes in the UK – screening and monitoring



SPEAKER
DR. PETER JOHANSSON
(Sweden)

Implementing a one stop shop for diabetes check-ups in a health care setting in Sweden



SPEAKER
DR. ENRICO TORRE
(Italy)

Perspective from Italy on diabetes patients testing before and during the COVID-19 pandemic



SPEAKER
PROF. NEALE COHEN
(Australia)

Alternative ways to manage diabetes patients during COVID-19. The point of care testing drive through experience in Australia



SPEAKER
DR. ERNA LENTERS-WESTRA
(The Netherlands)

Can high accuracy be achieved with point-of-care testing?



REGISTER FOR MYPOCACADEMY IT'S FREE

THIS LIVESTREAM WILL BE HOSTED ON THE MYPOCACADEMY WEBSITE.

MyPOCAcademy is a new, interactive educational resource providing information on the rationale for point-of-care testing and its value across a number of medical specialties. MyPOCAcademy offers CPD/CME accredited courses that allow you to enhance your knowledge and skills at your own pace.

MYPOCACADEMY IS FREE TO JOIN AND OFFERS A PROFESSIONAL BLENDED LEARNING CONTINUUM.

Within each course are test questions that allow you to test your knowledge. Interactive patient case studies enable you to view the benefits of point-of-care testing in real-life clinical scenarios.

1. World Health Organisation. Clinical management of COVID-19: Interim guidance, 27 May 2020. WHO/2019-nCoV/clinical/2020.5.
2. Riddle M, Buse JB, Franks PW, et al. COVID-19 in People With Diabetes: Urgently needed Lessons From Early Reports. *Diabetes Care*. Published online May 14, 2020.
3. Centers for Disease Control and Prevention. COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12–March 28, 2020. *Morbidity and Mortality Weekly Report*. April 3, 2020;69(13):382-386. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm>.
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalised With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052-2059.
5. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalised in the United States. *J Diabetes Sci Technol*. Published online May 9, 2020.
6. Palmieri L, Andrianou X, Barbariol P, et al. COVID-19 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 20, 2020. EpiCentro. https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_20_April_2020.pdf. Accessed June 5, 2020.
7. Chen Y, Yang D, Cheng B. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose Lowering Medication. *Diabetes Care*. Published online May 14, 2020.
8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med*. 2020;382:1708-20.
9. Lian J, Liang Y. *Curr Med Res & Op*. 2014;30(11):2233-2240.
10. Egbunike V, Gerard S. *Diabetes Educator*. 2013;39(1):66-73.
11. Lee-Lewandrowski L, Yeh S, Baron J, Crocker JB, Lewandrowski K. *Clin Chim Acta*. 2017;473:71-74.
12. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. *AJCP*. 2014;142:640-646.

